Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
BLS Pharmaceuticals (ASX:BLS), formerly Bioxyne, is a rapidly growing licensed manufacturer of controlled medicines backed by small-cap investors. In August 2026, DMX Asset Management reported a strong result at the top of guidance, with revenue up 161% to $74.2 million, adjusted EBITDA of $19 million and profit of $15.4 million, along with FY27 revenue guidance of $105 million. Cyan described the company as the largest licensed manufacturer and wholesaler of medicinal cannabis, psilocybin and MDMA, and Tamim noted it is cash flow positive. Bioxyne operates in the Healthcare sector within the Life Sciences Tools and Services industry, and Thesis Tracker has captured 13 comments from 3 fund managers, DMX Asset Management, Cyan and Tamim. Founded in 1998 and headquartered in Sydney, BLS Pharmaceuticals manufactures and distributes GMP-licensed finished-dose medicines, including medicinal cannabis, MDMA and psilocybin, in Australia and internationally.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Cyan Investment Management, Tamim Funds Management and DMX Asset Management have invested in Bioxyne Ltd (ASX:BLS).
Managers highlight rapid revenue and profit growth, guidance for FY27 revenue of $105 million, a leading position in licensed controlled medicines and tailwinds in Australia and internationally, according to DMX, Cyan and Tamim.
The commentary is positive but notes share price volatility, including an 8% fall in a single month, and the business operates in a heavily regulated area of controlled substances.
Bioxyne Ltd., founded in 1998 and headquartered in Sydney, Australia, researches, develops, and distributes health products. The company operates through three segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment manages operations across the USA and Asia. The Plant Based segment focuses on the manufacturing and distribution of plant-based products. The Direct Sales segment serves markets in Australia and Asia. Bioxyne Ltd. provides these health solutions globally through its multi-channel distribution model.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.